EGFR inhibitors are efficacious as second-line or third-line treatment for advanced non-small-cell lung cancer (NSCLC). Treatment with these inhibitors is particularly favorable in women ...

Sixty lung adenocarcinomas that were known to be sensitive or refractory to single-agent gefitinib or erlotinib were analyzed. Each tumor specimen was screened for mutations in EGFR exons 18–21 ...